Non–small cell lung cancer (NSCLC) encompasses a heterogeneous patient population whose clinical needs, biological features, and treatment outcomes differ substantially from those represented in pivotal studies. Adolescents and young adults (AYA), women, pregnant patients, individuals with actionable genomic alterations (AGAs) or constitutional pathogenic variants (CPVs), immunocompromised patients, including those with chronic viral infections, older adults, patients with brain metastases, and survivors with second primary lung cancers (SPLC) remain consistently underrepresented in research programs.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 30 Mar 2026.
The item focuses on Non-Small Cell Lung Cancer (NSCLC) in Vulnerable and Special Populations: Towards Personalized Care.
Review the original article for the full source wording and details.